AMG 333

Phase 2Small molecule

Amgen

AMG 333 is one of 328 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

182

Total Trials

Active Trials

327

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerTerminated

Advanced Solid TumorsCompleted

OsteoporosisActive, not recruiting

Prostate CancerCompleted

AsthmaCompleted

Thyroid Eye DiseaseRecruiting

Lung CancerActive, not recruiting

Advanced or Metastatic Solid TumorsRecruiting

Solid TumorsActive, not recruiting

Thoracic TumorsRecruiting

Pancreatic CancerPhase 1

Terminated

Advanced Solid TumorsPhase 1

Completed

OsteoporosisPreclinical

Active, not recruiting

Prostate CancerPhase 2

Completed

AsthmaPhase 2

Completed

Thyroid Eye DiseasePhase 2

Recruiting

Lung CancerPhase 2

Active, not recruiting

Advanced or Metastatic Solid TumorsPhase 1

Recruiting

Solid TumorsPhase 2

Active, not recruiting

Thoracic TumorsPhase 1

Recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 2

Paraplatin

AAvyxa

Phase 3

25 3

LHRH Agonist

Roche

Phase 3

10 4

Leuprorelin

Takeda

Phase 3

9 5

Acetylsalicylic Acid

Bayer

Phase 3

2 6

Perflutren Lipid Microspheres

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 3

1 7

AMG 333

Amgen

Phase 2

2 8

Trexall

Duragesic

1 10

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Cardiometabolic Disease

NCT06585462

Q2 2027

Phase 1Recruiting

Asthma

NCT06637371

Q4 2027

Phase 2Active, not recruiting

Lung Cancer

NCT05118854

Phase 1Active, not recruiting

Advanced Solid Tumors

NCT04185883

PreclinicalActive, not recruiting

Thyroid Eye Disease

NCT06401044

Q2 2028

Phase 1/2Active, not recruiting

Advanced MTAP-Null Solid Tumors

NCT05094336

Clinical

Trials by Indication[1]

Advanced Solid Tumors8 trials

Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Completed· Amgen logo

Amgen·Phase 1·NCT05800964·37 enrolled

A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors

Terminated· Amgen logo

Amgen·Phase 1·NCT01137552·44 enrolled

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors

Completed· Amgen logo

Amgen·Phase 1·NCT04727554·11 enrolled

Show 5 more trials

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT04185883·610 enrolled

Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors

Completed· Amgen logo

Amgen·Phase 1·NCT00448786·49 enrolled

Study of AMG 256 in Adult Subjects With Advanced Solid Tumors

Completed· Amgen logo

Amgen·Phase 1·NCT04362748·34 enrolled

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Completed· Amgen logo

Amgen·Phase 1·NCT00093873·71 enrolled

A Phase 1/1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 436 as Monotherapy and in Combination With Other Therapies in Participants With Microsatellite Instability-high (MSI-H)/Mismatch Repair Deficient (dMMR) Solid Tumors

Recruiting· Amgen logo

Amgen·Phase 1·NCT07403721·464 enrolled

Tics8 trials

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05885451·18 enrolled

A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05581758·14 enrolled

A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05599828·14 enrolled

Show 5 more trials

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects

Completed· Amgen logo

Amgen·Phase 1·NCT01695876·58 enrolled

Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05598281·14 enrolled

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

Completed· Amgen logo

Amgen·Phase 1·NCT03626662·79 enrolled

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Completed· Amgen logo

Amgen·Phase 1·NCT01290042·43 enrolled

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject

Completed· Amgen logo

Amgen·Phase 1·NCT02348879·51 enrolled

Systemic Lupus Erythematosus6 trials

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

Completed· Amgen logo

Amgen·Phase 1·NCT02391259·57 enrolled

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus

Completed· Amgen logo

Amgen·Phase 1·NCT02411136·64 enrolled

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

Completed· Amgen logo

Amgen·Phase 1·NCT00774943·58 enrolled

Show 3 more trials

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus

Completed· Amgen logo

Amgen·Phase 1·NCT02443506·56 enrolled

Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

Completed· Amgen logo

Amgen·Phase 1·NCT00818948·56 enrolled

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus

Completed· Amgen logo

Amgen·Phase 1·NCT02291588·26 enrolled

Non-Small Cell Lung Cancer5 trials

A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

Terminated· Amgen logo

Amgen·Phase 1·NCT05317078·3 enrolled

Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer

Completed· Amgen logo

Amgen·Phase 1/2·NCT01666977·36 enrolled

A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab

Completed· Amgen logo

Amgen·Phase 2·NCT00508625·213 enrolled

Show 2 more trials

Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer

Withdrawn· Amgen logo

Amgen·Phase 1·NCT00352950

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Terminated· Amgen logo

Amgen·Phase 1·NCT04822298·3 enrolled

Breast Cancer5 trials

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Completed· Amgen logo

Amgen·Phase 2·NCT00511459·228 enrolled

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Completed· Amgen logo

Amgen·Phase 1·NCT00322400·46 enrolled

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Terminated· Amgen logo

Amgen·Phase 2·NCT00356681·282 enrolled

Show 2 more trials

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Completed· Amgen logo

Amgen·Phase 3·NCT00089661·252 enrolled

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Completed· Amgen logo

Amgen·Phase 1·NCT00807859·65 enrolled

98 more indications

Asthma5 trials

Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma

Completed· Amgen logo

Amgen·Phase 1·NCT01137565·23 enrolled

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Recruiting· Amgen logo

Amgen·Phase 1·NCT06637371·124 enrolled

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

Completed· Amgen logo

Amgen·Phase 2·NCT01199289·315 enrolled

Show 2 more trials

AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

Completed· Amgen logo

Amgen·Phase 2·NCT01018550·397 enrolled

AMG 761 in Adults With Asthma

Terminated· Amgen logo

Amgen·Phase 1·NCT01514981·7 enrolled

Migraine4 trials

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

Completed· Amgen logo

Amgen·Phase 1·NCT01953341·74 enrolled

AMG 334 20160172 Pediatric Migraine PK Study.

Completed· Amgen logo

Amgen·Phase 1·NCT03499119·53 enrolled

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Completed· Amgen logo

Amgen·Phase 2·NCT03238781·343 enrolled

Show 1 more trial

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

Terminated· Amgen logo

Amgen·Phase 1·NCT02132429·16 enrolled

Interaction4 trials

A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05568082·14 enrolled

AMG 386 Drug-Drug Interaction Study With Paclitaxel

Completed· Amgen logo

Amgen·Phase 1·NCT01992341·35 enrolled

A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05577624·14 enrolled

Show 1 more trial

Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05581992·14 enrolled

Rheumatoid Arthritis4 trials

Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis

Terminated· Amgen logo

Amgen·Phase 1·NCT02499315·32 enrolled

A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis

Completed· Amgen logo

Amgen·Phase 2·NCT00293826·813 enrolled

A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate

Completed· Amgen logo

Amgen·Phase 2·NCT00038298·53 enrolled

Show 1 more trial

Phase 2 AMG 714 in Rheumatoid Arthritis

Completed· Amgen logo

Amgen·Phase 2·NCT00433875·180 enrolled

Schizophrenia4 trials

20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

Terminated· Amgen logo

Amgen·Phase 2·NCT01568229·111 enrolled

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

Completed· Amgen logo

Amgen·Phase 1·NCT02504476·52 enrolled

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Terminated· Amgen logo

Amgen·Phase 2·NCT01568216·121 enrolled

Show 1 more trial

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

Terminated· Amgen logo

Amgen·Phase 1·NCT01568203·50 enrolled

Multiple Myeloma4 trials

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Terminated· Amgen logo

Amgen·Phase 1·NCT03836053·23 enrolled

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Withdrawn· Amgen logo

Amgen·Phase 1·NCT04998747

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Terminated· Amgen logo

Amgen·Phase 1·NCT03287908·174 enrolled

Show 1 more trial

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 1·NCT02561962·42 enrolled

Solid Tumors3 trials

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Active, not recruiting· Amgen logo

Amgen·Phase 1/2·NCT05975073·53 enrolled

A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

Completed· Amgen logo

Amgen·Phase 1·NCT01235416·57 enrolled

Safety Study of AMG 228 to Treat Solid Tumors

Terminated· Amgen logo

Amgen·Phase 1·NCT02437916·30 enrolled

Obesity3 trials

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

Completed· Amgen logo

Amgen·Phase 1·NCT05406115·65 enrolled

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

Terminated· Amgen logo

Amgen·Phase 1·NCT04199351·60 enrolled

Multiple Ascending Dose Study of AMG 598 in Adults With Obesity

Completed· Amgen logo

Amgen·Phase 1·NCT03757130·50 enrolled

Acute Myeloid Leukemia3 trials

Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

Terminated· Amgen logo

Amgen·Phase 1·NCT04478695·1 enrolled

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Terminated· Amgen logo

Amgen·Phase 1·NCT02675452·141 enrolled

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Terminated· Amgen logo

Amgen·Phase 1·NCT03541369·64 enrolled

Patients With Advanced Solid Tumors3 trials

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

Completed· Amgen logo

Amgen·Phase 1·NCT00102830

Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors

Completed· Amgen logo

Amgen·Phase 1·NCT01386866·4 enrolled

AMG 404 in Patients With Advanced Solid Tumors

Completed· Amgen logo

Amgen·Phase 1·NCT03853109·171 enrolled

ART3 trials

Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants

Terminated· Amgen logo

Amgen·Phase 1·NCT06910709·48 enrolled

A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05571163·13 enrolled

Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05056246·34 enrolled

Secondary Hyperparathyroidism3 trials

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

Completed· Amgen logo

Amgen·Phase 3·NCT00037635·400 enrolled

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

Completed· Amgen logo

Amgen·Phase 2·NCT00110929·850 enrolled

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis

Completed· Amgen logo

Amgen·Phase 3·NCT00042653·380 enrolled

Efficacy3 trials

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Terminated· Amgen logo

Amgen·Phase 3·NCT00460317·1,450 enrolled

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

Suspended· Amgen logo

Amgen·Phase 1·NCT03392064·6 enrolled

Phase II Study to Evaluate the Efficacy of AMG 317

Completed· Amgen logo

Amgen·Phase 2·NCT00436670·294 enrolled

ESS2 trials

AMG 714 Expanded Access Program

No longer available· Amgen logo

Amgen··NCT03439475

AMG 701 Expanded Access Program

No longer available· Amgen logo

Amgen··NCT05256446

Ovarian Cancer2 trials

Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer

Completed· Amgen logo

Amgen·Phase 1·NCT01253681·27 enrolled

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Terminated· Amgen logo

Amgen·Phase 3·NCT01493505·1,015 enrolled

Celiac Disease2 trials

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Completed· Amgen logo

Amgen·Phase 2·NCT02633020·28 enrolled

A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease

Completed· Amgen logo

Amgen·Phase 2·NCT02637141·64 enrolled

Impaired Renal Function2 trials

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

Completed· Amgen logo

Amgen·Phase 1·NCT03318809·12 enrolled

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Completed· Amgen logo

Amgen·Phase 1·NCT01331941·35 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of AMG 827 in Subjects With RA

Terminated· Amgen logo

Amgen·Phase 2·NCT01059448·211 enrolled

Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects

Completed· Amgen logo

Amgen·Phase 3·NCT00527267·320 enrolled

Overweight2 trials

A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity

Completed· Amgen logo

Amgen·Phase 1·NCT07310563·59 enrolled

A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity

Completed· Amgen logo

Amgen·Phase 1·NCT06976372·120 enrolled

Psoriasis2 trials

AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects

Completed· Amgen logo

Amgen·Phase 2·NCT00443326·22 enrolled

Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Terminated·BBausch Health Americas, Inc.·Phase 2·NCT01101100·181 enrolled

Type 2 Diabetes Mellitus2 trials

Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

Terminated· Amgen logo

Amgen·Phase 1·NCT01755442·5 enrolled

A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus

Withdrawn· Amgen logo

Amgen·Phase 2·NCT00661921

Advanced NSCLC2 trials

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Terminated· Amgen logo

Amgen·Phase 2·NCT00369070·186 enrolled

A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Recruiting· Amgen logo

Amgen·Phase 2·NCT06593522·200 enrolled

Pancreatic Cancer2 trials

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06360354·350 enrolled

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Terminated· Amgen logo

Amgen·Phase 1·NCT04117958·58 enrolled

Gastrointestinal Stromal Tumor2 trials

Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)

Completed· Amgen logo

Amgen·Phase 2·NCT00089960·138 enrolled

Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors

Completed· Amgen logo

Amgen·Phase 2·NCT00254267·35 enrolled

Low Bone Mineral Density2 trials

An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density

Completed· Amgen logo

Amgen·Phase 1·NCT01101048·74 enrolled

An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density

Completed· Amgen logo

Amgen·Phase 3·NCT00325468·200 enrolled

Type 2 Diabetes2 trials

Single Ascending Dose Trial in Patients With Type 2 Diabetes

Terminated· Amgen logo

Amgen·Phase 1·NCT01492465·47 enrolled

Multiple Ascending Dose Study in Subjects With Type 2 Diabetes

Terminated· Amgen logo

Amgen·Phase 1·NCT01856881·86 enrolled

Small Cell Lung Cancer2 trials

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Completed· Amgen logo

Amgen·Phase 1·NCT04885998·23 enrolled

A Multicenter, Open-label, Single-arm, Expanded Access Protocol of Sotorasib for the Treatment of Subjects With Previously Treated Locally Advanced Unresectable/Metastatic NSCLC With KRAS p.G12C Mutation

No longer available· Amgen logo

Amgen··NCT04667234

Prostate Cancer2 trials

AMG 386 and Abiraterone for Advanced Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01553188·36 enrolled

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Recruiting· Amgen logo

Amgen·Phase 1·NCT04221542·479 enrolled

Thyroid Eye Disease2 trials

A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease

Active, not recruiting· Amgen logo

Amgen·Preclinical·NCT06401044·94 enrolled

An Open-label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-sponsored AMG 732 Studies and Are Primary Proptosis Non-responders or Who Relapsed During the Safety Follow-up

Recruiting· Amgen logo

Amgen·Phase 2·NCT07438405·30 enrolled

Double-blind1 trial

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Completed· Amgen logo

Amgen·Phase 2·NCT00306189·212 enrolled

Atopic Asthma1 trial

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

Completed· Amgen logo

Amgen·Phase 1·NCT01928368·70 enrolled

Impairment1 trial

A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body

Completed· Amgen logo

Amgen·Phase 1·NCT07429045·44 enrolled

Myeloid Malignancies1 trial

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

Terminated· Amgen logo

Amgen·Phase 1·NCT02520427·95 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Terminated· Amgen logo

Amgen·Phase 1·NCT03571828·10 enrolled

Glioblastoma1 trial

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

Terminated· Amgen logo

Amgen·Phase 1·NCT03296696·30 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Terminated· Amgen logo

Amgen·Phase 1·NCT04260191·15 enrolled

Thyroid Cancer1 trial

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT00121628·184 enrolled

Hepatocellular Cancer1 trial

A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT00872014·60 enrolled

Gastric Emptying1 trial

The Effect of AMG 133 on Gastric Emptying

Completed· Amgen logo

Amgen·Phase 1·NCT07429032·57 enrolled

Recurrent Epithelial Ovarian1 trial

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT00479817·161 enrolled

Primary Hyperparathyroidism1 trial

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Completed· Amgen logo

Amgen·Phase 4·NCT00037518·46 enrolled

Prostate Carcinoma1 trial

A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Terminated· Amgen logo

Amgen·Phase 1·NCT04740034·42 enrolled

Hepatic Impairment1 trial

A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function

Completed· Amgen logo

Amgen·Phase 1·NCT07428525·36 enrolled

Sorafenib1 trial

AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib

Completed· Amgen logo

Amgen·Phase 2·NCT00467025·152 enrolled

Renal Cell Carcinoma1 trial

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

Completed· Amgen logo

Amgen·Phase 2·NCT00422019·61 enrolled

Kidney Cancer1 trial

AMG 172 First in Human Study in Patients With Kidney Cancer

Completed· Amgen logo

Amgen·Phase 1·NCT01497821·37 enrolled

Muscle Loss1 trial

AMG 745 in Subjects With Age-associated Muscle Loss

Withdrawn· Amgen logo

Amgen·Phase 2·NCT00975104

TED1 trial

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Completed· Amgen logo

Amgen·Phase 3·NCT00950911·35 enrolled

Advanced Cancer1 trial

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Terminated· Amgen logo

Amgen·Phase 1·NCT00101907·41 enrolled

Bevacizumab1 trial

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Completed· Amgen logo

Amgen·Phase 1·NCT00861419·88 enrolled

Fallopian Tube Cancer1 trial

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Completed· Amgen logo

Amgen·Phase 3·NCT01204749·919 enrolled

Cutaneous Lupus Erythematosus1 trial

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

Terminated· Amgen logo

Amgen·Phase 1·NCT01389895·1 enrolled

Metastatic Prostate Cancer1 trial

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Completed· Amgen logo

Amgen·Phase 3·NCT00089674·1,468 enrolled

Malignant Glioma1 trial

A Phase II Study to Treat Advanced Malignant Glioma

Completed· Amgen logo

Amgen·Phase 2·NCT00427440·61 enrolled

Chronic Rhinosinusitis With Nasal Polyps1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

Completed· Amgen logo

Amgen·Phase 1·NCT02170337·41 enrolled

Adult Subject1 trial

Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects

Completed· Amgen logo

Amgen·Phase 1·NCT01124279·43 enrolled

Intestinal Cancer1 trial

A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

Terminated· Amgen logo

Amgen·Phase 1·NCT02291614·45 enrolled

Malignancy1 trial

AMG 319 Lymphoid Malignancy FIH

Completed· Amgen logo

Amgen·Phase 1·NCT01300026·28 enrolled

Metastatic Colorectal Cancer1 trial

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Completed· Amgen logo

Amgen·Phase 1·NCT00101894·119 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

Completed· Amgen logo

Amgen·Phase 1·NCT04857606·47 enrolled

Thoracic Tumors1 trial

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Recruiting· Amgen logo

Amgen·Phase 1·NCT06333951·500 enrolled

Absorption1 trial

A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects

Completed· Amgen logo

Amgen·Phase 1·NCT05578859·8 enrolled

Postmenopausal Women1 trial

A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women

Completed· Amgen logo

Amgen·Phase 1·NCT00902356·69 enrolled

Relapsed or Refractory1 trial

Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL

Completed· Amgen logo

Amgen·Phase 1·NCT04524455·17 enrolled

Single Ascending Dose1 trial

Single Ascending Dose Study of AMG 570 in Healthy Subjects

Completed· Amgen logo

Amgen·Phase 1·NCT02618967·56 enrolled

Immunogenicity1 trial

A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05873907·64 enrolled

Drug Interactions1 trial

Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05550129·13 enrolled

Ulcerative Colitis1 trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Terminated· Amgen logo

Amgen·Phase 1·NCT01164904·72 enrolled

Hematological Malignancies1 trial

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Terminated· Amgen logo

Amgen·Phase 1·NCT03465540·24 enrolled

Chronic Myelomonocytic Leukemia1 trial

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Terminated· Amgen logo

Amgen·Phase 1·NCT05209152·7 enrolled

Hematologic Malignancies1 trial

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Terminated· AbbVie logo

AbbVie·Phase 1·NCT03797261·9 enrolled

Treatment1 trial

An Open Label Treatment Extension Study of AMG 706

Terminated· Amgen logo

Amgen·Phase 2·NCT00360867·94 enrolled

Osteoarthritis1 trial

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain

Completed· Amgen logo

Amgen·Phase 1·NCT02318407·24 enrolled

Renal Osteodystrophy1 trial

12-month Study of AMG 073 in Renal Osteodystrophy

Completed· Amgen logo

Amgen·Phase 2·NCT00527085·45 enrolled

Anemia1 trial

A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy

Terminated· Amgen logo

Amgen·Phase 1/2·NCT00119600

Vitiligo1 trial

Evaluation of AMG 714 for Vitiligo

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04338581·60 enrolled

Relapsed/Refractory AML1 trial

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Withdrawn· Amgen logo

Amgen·Phase 1·NCT03904069

Urothelial Carcinoma1 trial

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

Withdrawn·UUniversity of Colorado, Denver·Phase 2·NCT01907308

Glioma1 trial

AMG 595 First-in-Human in Recurrent Gliomas

Completed· Amgen logo

Amgen·Phase 1·NCT01475006·32 enrolled

Advanced MTAP-null Solid Tumors1 trial

A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Active, not recruiting· Amgen logo

Amgen·Phase 1/2·NCT05094336·329 enrolled

Esophageal Adenocarcinoma1 trial

Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma

Completed· Amgen logo

Amgen·Phase 2·NCT00583674·171 enrolled

Phase 11 trial

A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)

Completed· Amgen logo

Amgen·Phase 1·NCT00756860·66 enrolled

Function1 trial

Long-Term Assessment of Safety and Physical Function With AMG 108 in RA

Completed· Amgen logo

Amgen·Phase 2·NCT00369473·690 enrolled

Neuroendocrine Tumors1 trial

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00427349·46 enrolled

Colorectal Carcinoma1 trial

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Completed· Amgen logo

Amgen·Phase 2·NCT00752570·144 enrolled

Arthritis1 trial

Safety Study of AMG 557 in Subjects With Lupus Arthritis

Completed· Amgen logo

Amgen·Phase 1·NCT01683695·20 enrolled

Metastasis1 trial

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Withdrawn·CCriterium, Inc.·Phase 1/2·NCT05180422

Postmenopausal Osteoporosis1 trial

Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

Completed· Amgen logo

Amgen·Phase 3·NCT00091793·332 enrolled

Chronic Kidney Disease1 trial

Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia

Completed· Amgen logo

Amgen·Phase 2·NCT00530114·167 enrolled

Heart Failure1 trial

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

Terminated· Amgen logo

Amgen·Phase 1·NCT03276728·182 enrolled

Osteoporosis1 trial

Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France

Completed· Amgen logo

Amgen··NCT02347865·777 enrolled

Cardiometabolic Disease1 trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT06585462·82 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Terminated· EMD Serono logo

EMD Serono·Preclinical·NCT04631601·55 enrolled

Solid Tumor1 trial

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Completed· Amgen logo

Amgen·Phase 1·NCT06131398·77 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Recruiting· Amgen logo

Amgen·Phase 1·NCT07094113·434 enrolled

KRAS p, G12c Mutated /Advanced Metastatic NSCLC1 trial

A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Completed· Amgen logo

Amgen·Phase 3·NCT04303780·345 enrolled

Lung Cancer1 trial

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05118854·13 enrolled

Unspecified4 trials

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Completed· Amgen logo

Amgen·Phase 1·NCT04380753·12 enrolled

AMG 151 Amgen Protocol Number 20100761

Completed· Amgen logo

Amgen·Phase 2·NCT01464437·236 enrolled

AMG 529 First in Human Study

Completed· Amgen logo

Amgen·Phase 1·NCT03170193·48 enrolled

Show 1 more trial

Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581

Completed· Amgen logo

Amgen·Phase 1·NCT02567370·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 182 trial records for AMG 333. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMG 333 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMG 333. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Amgen